

1 **Title Page**

2

3 **Article Type:** Research Article

4

5 **Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of  
6 bacterial pathogens

7

8 **Authors:** Christine Tedijanto,<sup>1</sup> Yonatan H Grad,<sup>2,3</sup> Marc Lipsitch<sup>1,2</sup>

9

10 **Author Affiliations:** <sup>1</sup> Center for Communicable Disease Dynamics, Department of  
11 Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;  
12 <sup>2</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public  
13 Health, Boston, Massachusetts, USA; <sup>3</sup> Division of Infectious Diseases, Brigham and Women's  
14 Hospital, Harvard Medical School, Boston, Massachusetts, USA

15

16 **Corresponding Author:** Christine Tedijanto, [ctedijanto@g.harvard.edu](mailto:ctedijanto@g.harvard.edu)

17

18 **Manuscript Word Count:** 3,025

19

20 **Abstract**

21 The relationship between antibiotic stewardship and population levels of antibiotic resistance  
22 remains unclear. In order to better understand shifts in selective pressure due to stewardship, we  
23 use publicly available data to estimate the effect of changes in prescribing on exposures to  
24 frequently used antibiotics experienced by potentially pathogenic bacteria that are  
25 asymptotically colonizing the microbiome. We quantify this impact under four hypothetical  
26 stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient  
27 antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations  
28 of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that  
29 stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics,  
30 have the opportunity to broadly reduce antibiotic exposures across a range of potential  
31 pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are  
32 needed to further decrease exposures occurring in “necessary” contexts.

33

## 34 **Introduction**

35 Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over  
36 80% of antibiotic consumption for human health occurs in the outpatient setting (European  
37 Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public  
38 Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different  
39 subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate  
40 (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden,  
41 Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events  
42 (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance  
43 and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013),  
44 and bystander selection for antibiotic resistance, with little to no health gains for the patient.  
45 Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over  
46 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when  
47 the organisms are asymptotically colonizing the microbiome, not causing disease (Tedijanto,  
48 Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions  
49 in use will prevent antibiotic exposures for species throughout the microbiome.

50  
51 We use publicly available data to quantify potentially avertable exposures of bacterial species to  
52 commonly used antibiotics under hypothetical changes in prescribing practice. The set of  
53 scenarios included here are intended as thought experiments to explore the upper bounds of  
54 avertable antibiotic exposures. Reductions in antibiotic consumption have historically had  
55 variable impacts on resistance levels, likely dependent on setting, baseline consumption and  
56 resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

57 treatment strategies are primarily guided by randomized controlled trials assessing immediate  
58 clinical outcomes, with less careful consideration given to the microbiome-wide effect of such  
59 decisions. We apply analytical methods to parse out species-level effects of changes in  
60 prescribing practice in order to better understand the potential impact of antibiotic stewardship.

61

## 62 **Methods**

### 63 *Scenarios of interest*

64 This analysis includes sixteen antibiotics that are frequently prescribed in the outpatient setting  
65 and nine potentially pathogenic bacterial species that are commonly carried in the normal human  
66 microbiome. For each antibiotic-species pair, we estimate the proportion of antibiotic exposures  
67 experienced by that species that could be averted under four hypothetical scenarios. The  
68 scenarios range from broad elimination of unnecessary prescribing to focused modifications of  
69 antibiotic use for specific indications as follows:

- 70 1) Eliminate unnecessary antibiotic use across all outpatient conditions.
- 71 2) Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics are  
72 not indicated.
- 73 3) Eliminate all antibiotic use for acute sinusitis.
- 74 4) Prescribe nitrofurantoin for all cases of cystitis in women.

75 Based on previously published work, we consider viral upper respiratory tract infection,  
76 influenza, non-suppurative otitis media, viral pneumonia, bronchitis, and allergy and asthma to  
77 be outpatient respiratory conditions for which antibiotics are not indicated (Fleming-Dutra et al.,  
78 2016). Due to the self-limiting nature and infrequent bacterial etiology of acute sinusitis, there is  
79 weak evidence to support antibiotic treatment (Burgstaller, Steurer, Holzmann, Geiges, & Soyka,

80 2016; Rosenfeld et al., 2015). However, antibiotics continue to be prescribed at over 80% of US  
81 outpatient visits with a primary diagnosis of acute sinusitis (Smith et al., 2013). In contrast,  
82 antibiotics are always recommended for urinary tract infections (UTIs). Despite being  
83 recommended as a second-line therapy for cystitis due to concerns about resistance,  
84 fluoroquinolones are the most common treatment, prescribed at 40% of outpatient visits for  
85 uncomplicated UTI (Kabbani et al., 2018). We explore the hypothetical scenario of treating all  
86 cases of cystitis in women with nitrofurantoin, a recommended first-line therapy with good  
87 potency against common uropathogens, low levels of resistance, and decreased risk of collateral  
88 damage to the intestinal microbiome due to its propensity to concentrate in the bladder (Gupta et  
89 al., 2011; Gupta, Scholes, & Stamm, 1999; Stewardson et al., 2015).

90

#### 91 *Data sources and methodology*

92 Extending our recent work on bystander selection (Tedijanto et al., 2018), we used the 2015  
93 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care  
94 Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012;  
95 The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies  
96 to estimate national outpatient antibiotic exposures by drug, species, and condition.  
97 NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in  
98 the United States, and up to five diagnoses and thirty medications may be associated with each  
99 visit. We used methodology developed by Fleming-Dutra and colleagues (Fleming-Dutra et al.,  
100 2016), and applied in other studies (Olesen et al., 2018), to group diagnosis codes into conditions  
101 and link antibiotic prescriptions with the most likely indication. For this analysis, visits with a  
102 diagnosis of acute cystitis (ICD-9-CM: 595.0), unspecified cystitis (595.9) or unspecified UTI

103 (599.0), without a concurrent diagnosis of pyelonephritis (590.1, 590.8), renal abscess (590.2), or  
104 kidney infection (590.9), were considered to be associated with cystitis. In this analysis, we  
105 maintain the assumption that one antibiotic prescription is equivalent to one exposure; antibiotic  
106 exposures experienced by a given species and associated with a given condition are roughly  
107 estimated as the product of antibiotic prescriptions for that condition and species carriage  
108 prevalence, which is dependent on disease etiology (target exposures) and asymptomatic carriage  
109 prevalence (bystander exposures) (details in Appendix Table 1). For diagnoses where etiology  
110 was not readily available, we assumed that none of our species of interest were causative agents.  
111 These assumptions have been enumerated in detail in prior work (Tedijanto et al., 2018).

112  
113 We applied proportions of unnecessary antibiotic prescribing by condition and age group  
114 estimated by Fleming-Dutra and colleagues based on expert opinion, clinical guidelines, and  
115 regional variability in use (Fleming-Dutra et al., 2016). Since these estimates were reported for  
116 oral antibiotic use in the outpatient setting, we excluded antibiotics that are typically  
117 administered topically or parenterally. For relevant scenarios (1 and 2), we applied the  
118 proportions of unnecessary use evenly across all antibiotic prescriptions.

119  
120 The proportion of avertable antibiotic exposures for each species is defined by Equation 1. The  
121 equation adopts previously described notation (Tedijanto et al., 2018) with modifications. A  
122 listing of all variables and descriptions can be found in Appendix Table 1. Let  $a$  represent  
123 antibiotic,  $s$  represent species,  $i$  represent ICD-9-CM diagnosis code, and  $g$  represent age group.  
124 Prescriptions with  $i=0$  were not associated with any ICD-9-CM diagnosis codes, and throughout  
125 the analysis we have weighted outpatient visits to be nationally representative. Let  $X_{as}$  be the

126 number of avertable exposures by antibiotic and species,  $T_{as}$  be the total number of exposures by  
127 antibiotic and species,  $d_{aig}$  be the number of prescriptions of antibiotic  $a$  associated with  
128 diagnosis code  $i$  in age group  $g$ ,  $p_{sig}$  be the carriage prevalence of species  $s$  among those with  
129 diagnosis code  $i$  in age group  $g$ , and  $q_{aig}$  be the proportion of avertable exposures by diagnosis  
130 code and age group in the given scenario. For example, in the scenario assessing elimination of  
131 all unnecessary antibiotic use,  $q_{aig}$  is the proportion of avertable antibiotic use by diagnosis and  
132 age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing elimination of  
133 non-nitrofurantoin treatment for cystitis,  $q_{aig}$  is 1 when  $a$  is not nitrofurantoin and  $i$  is a diagnosis  
134 code associated with cystitis, and 0 elsewhere. Carriage prevalences ( $p_{sig}$ ) are assumed to be  
135 constant within three age groups (under 1 year, 1-5 years, over 5 years old) (Tedijanto et al.,  
136 2018), while proportions of avertable antibiotic use ( $q_{aig}$ ) were reported for three different age  
137 groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-Dutra et al., 2016).  $G$  is the  
138 smallest set of age groups that accounts for this granularity (under 1 year, 1-5 years, 6-19 years,  
139 20-64 years, 65 years old and over).

140 **Equation 1.** Proportion of avertable exposures by species and antibiotic.

$$\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig}}$$

141  
142 In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander  
143 exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial  
144 and non-bacterial etiologies is possible. This results in a slight modification to Equation 1 --  $p_{sig}$   
145 is changed to  $p_{s0g}$  as all eliminated exposures would have occurred during asymptomatic  
146 carriage. For cases where  $e_{sig}$  is 1, we assume zero avertable exposures. In addition, we make  
147 slight modifications to  $q_{aig}$  when we estimate the proportion of bacterial cases to be larger than  
148 the proportion of necessary prescriptions (Appendix Table 2). As a sensitivity analysis, we

149 include the proportion of avertable exposures for each species-antibiotic pair under Scenario 1 if  
150 antibiotic use was eliminated equally across both target and bystander exposures (Appendix  
151 Figure 1). All analysis was conducted in R version 3.5.1.

152

## 153 **Results**


154 Results for all four scenarios are depicted in Figure 1. We estimate that elimination of  
155 unnecessary antibiotic prescriptions across all outpatient conditions would prevent 6 to 48%  
156 (IQR: 17 to 31%) of antibiotic-species exposures (Figure 1A). The smallest reduction is  
157 associated with *S. pyogenes* exposures to cefdinir and the largest with *H. influenzae* and *E. coli*  
158 exposures to azithromycin. If all unnecessary antibiotic use could be prevented, over 30% of  
159 exposures to amoxicillin-clavulanate, penicillin, azithromycin, clarithromycin, levofloxacin, and  
160 doxycycline across most potential pathogens of interest could be averted. As expected, the  
161 proportion of avertable exposures when all unnecessary outpatient use is eliminated is positively  
162 correlated with previously reported estimates of bystander selection (Appendix Figure 2)  
163 (Tedijanto et al., 2018).

164

165 Across all scenarios, the proportion of avertable exposures appears to be primarily driven by the  
166 drug considered. For example, in both scenarios assessing broad elimination of unnecessary  
167 antibiotic use, every species can expect azithromycin exposures to decrease to the greatest extent  
168 as it is the most commonly used antibiotic for respiratory conditions for which antibiotics are not  
169 indicated (Figure 1B). The estimated reductions in azithromycin across species range from 37 to  
170 48% when all outpatient conditions are considered and from 24 to 32% when limited to the  
171 subset of respiratory conditions for which antibiotics are not indicated. High estimates of



172 avertable exposures for a particular antibiotic reflect both frequent use for the impacted  
 173 syndrome(s) and concentrated use for those conditions relative to other indications. Consider the  
 174 indication-specific scenarios: ciprofloxacin and sulfamethoxazole-trimethoprim are the most  
 175 frequently prescribed antibiotics for cystitis other than nitrofurantoin and have relatively large  
 176 estimates of avertable exposures (23 to 44% and 7 to 26%, respectively). While clarithromycin is  
 177 only the eighth-most-prescribed antibiotic for acute sinusitis among the included antibiotics, its  
 178 concentrated use for acute sinusitis compared to other indications results in relatively large  
 179 expected reductions in exposure (up to 9% for *P. aeruginosa* and *S. pyogenes*) compared to other  
 180 drugs.



181 **Figure 1.** Heatmaps showing the estimated percentage of species exposures to each antibiotic or  
 182 antibiotic class that could be averted if *A*: unnecessary antibiotic prescriptions across all  
 183 outpatient conditions, *B*: all antibiotic use for outpatient respiratory conditions for which  
 184 antibiotics are not indicated, *C*: all antibiotic use for acute sinusitis, or *D*: non-nitrofurantoin  
 185

186 treatment of cystitis in women was eliminated. Drug class results include prescriptions of all  
187 antibiotics in that class, as identified by the Multum Lexicon classification system.

188 **Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,  
189 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,  
190 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,  
191 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;  
192 *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*,  
193 SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

194  
195 Characteristics of the bacterial organism of interest also influence the extent of avertable  
196 exposures. Species that are common causes of the affected condition(s) naturally have larger  
197 predicted reductions in exposure. For example, an estimated 33%, 36%, and 44% of  
198 ciprofloxacin exposures to *E. coli*, *K. pneumoniae*, and *P. aeruginosa*, respectively, could be  
199 averted under the cystitis scenario, compared to 23 to 27% across all other organisms. Although  
200 *E. coli* is the most common cause of UTIs, its estimated exposure reduction in this scenario is  
201 lower than that of *P. aeruginosa*, likely due to the larger number of bystander exposures incurred  
202 by *E. coli* during asymptomatic carriage. Infrequent carriage prevalence in the normal  
203 microbiome is also generally associated with lower proportions of avertable exposures across all  
204 antibiotics (e.g. *S. pyogenes*, *S. agalactiae*, *M. catarrhalis*).

205

## 206 **Discussion**

207 We quantify the species-level impact of changes in antibiotic consumption as the proportion of  
208 antibiotic exposures experienced by common bacterial pathogens that could be averted under  
209 four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient  
210 conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae* and *E. coli* to  
211 azithromycin) could be avoided. In addition, impact of the intervention across antibiotics and  
212 species is widespread, with half of antibiotic-species pairs expected to experience a reduction in  
213 exposures of over one fifth (22%). For conditions which require antibiotic treatment, such as

214 UTIs, switching to antibiotics with decreased collateral damage to the microbiome, such as  
215 nitrofurantoin, may be an effective strategy for reducing antibiotic exposures across species.

216

217 In three out of four situations we assess, antibiotics are considered entirely unnecessary for some  
218 or all cases. This is a strong assumption in the case of acute sinusitis, as a small number of cases  
219 are truly bacterial and antibiotics are indicated for patients with persistent, severe or worsening  
220 symptoms (Rosenfeld et al., 2015). These scenarios are explored in sensitivity analyses

221 (Appendix Figure 3). In the future, this method may also be extended to measure net changes in  
222 exposures resulting from more nuanced scenarios where one antibiotic is substituted for another.

223 We did not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the  
224 bladder are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here  
225 may be practically infeasible due to challenges including similar clinical presentation of viral and  
226 bacterial infections, individual considerations such as allergies (Sakoulas, Geriak, & Nizet, 2018)  
227 or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas, Getman, Donskey,  
228 & Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even if elimination of

229 unnecessary use were fully realized, our results imply that the majority of species' antibiotic  
230 exposures occur in the context of "necessary" antibiotic use. These findings underscore the

231 importance of considering bystander effects and the need for a multi-pronged approach to  
232 programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics that

233 accurately discriminate between bacterial and non-bacterial causes, patient education, and  
234 improved decision-making tools and other interventions to motivate changes in clinician

235 behavior can enhance responsible antibiotic consumption; these should be implemented

236 simultaneously with prevention measures such as infection control, access to clean water and

237 sanitation, safe sex interventions, and vaccination, which aim to reduce infection incidence and  
238 thus any antibiotic use.

239

240 At the time of this analysis, NHAMCS data from hospital outpatient departments was not yet  
241 available for years after 2011. In the 2010-2011 NAMCS/NHAMCS data, visits to hospital  
242 outpatient departments accounted for 36% of included sampled visits, but just 9% of all  
243 antibiotic mentions. The proportions of avertable exposures including and excluding these visits  
244 for 2010-2011 were similar (Appendix Figure 4); thus, we assumed that antibiotic use and  
245 diagnoses in the existing 2015 data without hospital outpatient department visits was  
246 representative. Additional limitations of the included datasets and method for estimating  
247 antibiotic exposures have been previously enumerated (Tedijanto et al., 2018). Notably, the  
248 NAMCS/NHAMCS does not provide information to link medications with diagnoses, so we  
249 adopted a published tiered system to pair antibiotic use at each visit with the most likely  
250 indication (Fleming-Dutra et al., 2016). For visits with multiple diagnoses, all antibiotic use was  
251 attributed to the single most-likely indication. This method tends to overestimate antibiotic use  
252 for conditions for which antibiotics are almost always indicated, which may lead to clinically  
253 unusual diagnosis-treatment linkages. In the same way, antibiotic prescriptions are  
254 underestimated for diagnoses for which antibiotic use is not indicated, potentially leading to  
255 downward bias in avertable exposures for these conditions. Additionally, NAMCS/NHAMCS  
256 antibiotic use data does not include prescription details such as duration or dose. However, the  
257 correlation between these factors and selection for resistance requires further study; prescriptions  
258 may be a sufficient measure (Bruyndonckx et al., 2014; Lipsitch, 2001).

259

260 At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of  
261 unnecessary antibiotic prescribing by condition. Recent work with slightly different methods  
262 found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to  
263 30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable  
264 estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that  
265 declines in antibiotic use from approximately 2011 to 2016 in the United States have been  
266 primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary  
267 prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts,  
268 & Hicks, 2019; Klevens et al., 2019; Olesen et al., 2018). Finally, we assume that the proportion  
269 of unnecessary use is constant across antibiotics used for the same condition as it is difficult to  
270 identify specific antibiotic prescriptions that were unwarranted without detailed chart review. A  
271 study among outpatients in the Veterans Affairs medical system found that among prescriptions  
272 for community-acquired pneumonia, sinusitis, and acute exacerbations of chronic bronchitis, the  
273 highest proportion of macrolide use was inappropriate (27%), followed by penicillins (22%) and  
274 quinolones (12%) (Tobia, Aspinall, Good, Fine, & Hanlon, 2008). Similar studies are needed to  
275 understand which antibiotics are frequently used inappropriately for other indications and  
276 settings.

277  
278 Reductions in antibiotic consumption are necessary to preserve the potency of these drugs.  
279 Quantifying changes in species-level exposures due to stewardship programs is one more step  
280 towards understanding how changes in antibiotic use correspond to antibiotic resistance at the  
281 population level. Further research, integrating knowledge from clinical, ecological, and  
282 evolutionary spheres, is needed to elucidate this relationship (MacLean & San Millan, 2019).

283 The methods presented here may be easily extended to incorporate other data sources, such as  
284 claims, or to assess more specific stewardship programs. We show that while improved  
285 prescribing practices have the potential to prevent antibiotic exposures experienced by bacterial  
286 species throughout the microbiome, complementary efforts to facilitate appropriate antibiotic  
287 consumption and decrease overall infection incidence are required to substantially avert  
288 exposures.

### 289 **Acknowledgements**

290 We thank Dr. Lauri Hicks for her helpful comments on this manuscript.

291

### 292 **Competing Interests**

293 ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and  
294 research grants through Harvard School of Public Health from Pfizer and PATH. YHG has  
295 received consulting income from Merck and GlaxoSmithKline. The authors have no other  
296 relationships or activities that could appear to have influenced the submitted work.

297

### 298 **Funding Sources**

299 This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study,  
300 Center for Communicable Disease Dynamics) from the National Institute of General Medical  
301 Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to  
302 YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris  
303 Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute  
304 of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and  
305 does not necessarily represent the official views of the National Institute of General Medical  
306 Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases,  
307 Centers for Disease Control and Prevention, Department of Health and Human Services, or the  
308 Doris Duke Charitable Foundation.

309

310

311 **References**

- 312
- 313 Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed  
314 Up by Primary Care Pediatricians. *Archives of Pediatrics & Adolescent Medicine*, 152(3),  
315 244–248. <https://doi.org/10.1001/archpedi.152.3.244>
- 316 Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse  
317 resistance? *Nature Reviews Microbiology*, 8(4), 260–271.  
318 <https://doi.org/10.1038/nrmicro2319>
- 319 Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated  
320 acute bacterial rhinosinusitis: Summary of the Agency for Health Care Policy and  
321 Research evidence-based report. *Otolaryngology–Head and Neck Surgery*, 122(1), 1–7.  
322 [https://doi.org/10.1016/S0194-5998\(00\)70135-5](https://doi.org/10.1016/S0194-5998(00)70135-5)
- 323 Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media  
324 pathogens. *The Pediatric Infectious Disease Journal*, 11(8), S7–S11.  
325 <https://doi.org/10.1097/00006454-199208001-00002>
- 326 Brook, I. (2016). Microbiology of chronic rhinosinusitis. *European Journal of Clinical*  
327 *Microbiology & Infectious Diseases*, 35(7), 1059–1068. [https://doi.org/10.1007/s10096-](https://doi.org/10.1007/s10096-016-2640-x)  
328 [016-2640-x](https://doi.org/10.1007/s10096-016-2640-x)
- 329 Bruyndonckx, R., Hens, N., Aerts, M., Goossens, H., Molenberghs, G., & Coenen, S. (2014).  
330 Measuring trends of outpatient antibiotic use in Europe: Jointly modelling longitudinal  
331 data in defined daily doses and packages. *Journal of Antimicrobial Chemotherapy*, 69(7),  
332 1981–1986. <https://doi.org/10.1093/jac/dku063>

- 333 Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against  
334 intestinal pathogens. *Nature Reviews Immunology*, *13*(11), 790–801.  
335 <https://doi.org/10.1038/nri3535>
- 336 Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic  
337 efficacy in patients with a moderate probability of acute rhinosinusitis: A systematic  
338 review. *European Archives of Oto-Rhino-Laryngology*, *273*(5), 1067–1077.  
339 <https://doi.org/10.1007/s00405-015-3506-z>
- 340 Celin, S. E. (1991). Bacteriology of Acute Otitis Media in Adults. *JAMA*, *266*(16), 2249–2252.  
341 <https://doi.org/10.1001/jama.266.16.2249>
- 342 Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic  
343 prescribing among privately insured US patients: ICD-10-CM based cross sectional  
344 study. *BMJ*, *364*(k5092). <https://doi.org/10.1136/bmj.k5092>
- 345 Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., &  
346 Fraser, V. J. (2018). Outpatient Antibiotic Prescription Trends in the United States: A  
347 National Cohort Study. *Infection Control & Hospital Epidemiology*, *39*(5), 584–589.  
348 <https://doi.org/10.1017/ice.2018.26>
- 349 European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption:*  
350 *Annual epidemiological report for 2017*. Stockholm.
- 351 Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R.  
352 (2015). Diagnostic Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control*  
353 *& Hospital Epidemiology*, *36*(8), 949–956. <https://doi.org/10.1017/ice.2015.113>
- 354 Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., ...  
355 Hicks, L. A. (2016). Prevalence of Inappropriate Antibiotic Prescriptions Among US



- 356            Ambulatory Care Visits, 2010-2011. *JAMA*, 315(17), 1864–1873.
- 357            <https://doi.org/10.1001/jama.2016.4151>
- 358    Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., ... Soper, D. E.
- 359            (2011). International Clinical Practice Guidelines for the Treatment of Acute
- 360            Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious
- 361            Diseases Society of America and the European Society for Microbiology and Infectious
- 362            Diseases. *Clinical Infectious Diseases*, 52(5), e103–e120.
- 363            <https://doi.org/10.1093/cid/ciq257>
- 364    Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial
- 365            resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA*,
- 366            281(8), 736–738. <https://doi.org/10.1001/jama.281.8.736>
- 367    Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., ...
- 368            White, O. (2012). Structure, function and diversity of the healthy human microbiome.
- 369            *Nature*, 486(7402), 207–214. <https://doi.org/10.1038/nature11234>
- 370    Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A.
- 371            (2018). Opportunities to Improve Fluoroquinolone Prescribing in the United States for
- 372            Adult Ambulatory Care Visits. *Clinical Infectious Diseases*, 67(1), 134–136.
- 373            <https://doi.org/10.1093/cid/ciy035>
- 374    Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for
- 375            microbial infections. *Current Opinion in Microbiology*, 16(2), 221–227.
- 376            <https://doi.org/10.1016/j.mib.2013.03.009>

- 377 King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019).  
378 Changes in US Outpatient Antibiotic Prescriptions from 2011-2016. *Clinical Infectious*  
379 *Diseases*. <https://doi.org/10.1093/cid/ciz225>
- 380 Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019).  
381 Outpatient antibiotic prescribing in Massachusetts, 2011-2015. *Open Forum Infectious*  
382 *Diseases*, 6(5), ofz169. <https://doi.org/10.1093/ofid/ofz169>
- 383 Linder, J. A. (2008). *Editorial Commentary*: Antibiotics for Treatment of Acute Respiratory  
384 Tract Infections: Decreasing Benefit, Increasing Risk, and the Irrelevance of  
385 Antimicrobial Resistance. *Clinical Infectious Diseases*, 47(6), 744–746.  
386 <https://doi.org/10.1086/591149>
- 387 Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, 9(9),  
388 438–444. [https://doi.org/10.1016/S0966-842X\(01\)02130-8](https://doi.org/10.1016/S0966-842X(01)02130-8)
- 389 MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. *Science*,  
390 365(6458), 1082–1083. <https://doi.org/10.1126/science.aax3879>
- 391 Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in  
392 outpatient antibiotic prescribing practice among US older adults, 2011-2015: An  
393 observational study. *BMJ*, 362, k3155. <https://doi.org/10.1136/bmj.k3155>
- 394 Public Health Agency of Canada. (2018). *Canadian Antimicrobial Resistance Surveillance*  
395 *System 2017 Report*.
- 396 Public Health England. (2017). *English Surveillance Programme for Antimicrobial Utilisation*  
397 *and Resistance (ESPAUR) 2017*.
- 398 Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper,  
399 M., ... Corrigan, M. D. (2015). Clinical Practice Guideline (Update): Adult Sinusitis.

- 400 *Otolaryngology–Head and Neck Surgery*, 152(2\_suppl), S1–S39.
- 401 <https://doi.org/10.1177/0194599815572097>
- 402 Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient
- 403 Grounds to Forgo the Multidimensional Antimicrobial Benefits of  $\beta$ -Lactam Antibiotics?
- 404 *Clinical Infectious Diseases*, 68, 157–164. <https://doi.org/10.1093/cid/ciy557>
- 405 Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis:
- 406 Continuing Challenges and Current Management. *Clinical Infectious Diseases*,
- 407 39(Supplement\_3), S151–S158. <https://doi.org/10.1086/421353>
- 408 Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits
- 409 for Antibiotic-Associated Adverse Events. *Clinical Infectious Diseases*, 47(6), 735–743.
- 410 <https://doi.org/10.1086/591126>
- 411 Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013).
- 412 National burden of antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical*
- 413 *Immunology*, 132(5), 1230–1232. <https://doi.org/10.1016/j.jaci.2013.07.009>
- 414 Snow, V., Mottur-Pilson, C., Hickner, J. M., & for the American College of Physicians–
- 415 American Society of Internal Medicine\*. (2001). Principles of Appropriate Antibiotic
- 416 Use for Acute Sinusitis in Adults. *Annals of Internal Medicine*, 134(6), 495.
- 417 <https://doi.org/10.7326/0003-4819-134-6-200103200-00016>
- 418 Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de
- 419 Tejada, B., ... Lazarevic, V. (2015). Collateral damage from oral ciprofloxacin versus
- 420 nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut
- 421 microbiota. *Clinical Microbiology and Infection*, 21(4), 344.e1-344.e11.
- 422 <https://doi.org/10.1016/j.cmi.2014.11.016>

- 423 Swedres-Svarm. (2017). *Consumption of antibiotics and occurrence of antibiotic resistance in*  
424 *Sweden*. Public Health Agency of Sweden and National Veterinary Institute.
- 425 Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of  
426 bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.  
427 *Proceedings of the National Academy of Sciences*, *115*(51), E11988–E11995.  
428 <https://doi.org/10.1073/pnas.1810840115>
- 429 The Human Microbiome Project Consortium. (2012). A framework for human microbiome  
430 research. *Nature*, *486*(7402), 215–221. <https://doi.org/10.1038/nature11209>
- 431 Tobia, C., Aspinall, S., Good, C., Fine, M., & Hanlon, J. (2008). Appropriateness of antibiotic  
432 prescribing in veterans with community-acquired pneumonia, sinusitis, or acute  
433 exacerbations of chronic bronchitis: A cross-sectional study. *Clinical Therapeutics*,  
434 *30*(6), 1135–1144. <https://doi.org/10.1016/j.clinthera.2008.06.009>
- 435 Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary  
436 Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women  
437 Presenting to an Emergency Department. *Journal of Clinical Microbiology*, *53*(8), 2686–  
438 2692. <https://doi.org/10.1128/JCM.00670-15>
- 439 Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., ... Besser, R.  
440 E. (2003). Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*,  
441 *9*(9), 1128–1135. <https://doi.org/10.3201/eid0909.020591>
- 442 Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young  
443 Children: Duration of and Frequency of Complications. *Pediatrics*, *87*(2), 129–133.

444 Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for  
445 Sinusitis. *Annals of Internal Medicine*, *117*(9), 705–710. [https://doi.org/10.7326/0003-](https://doi.org/10.7326/0003-4819-117-9-705)  
446 [4819-117-9-705](https://doi.org/10.7326/0003-4819-117-9-705)  
447  
448

449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475

## Supplementary Materials

**Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of bacterial pathogens

**Authors:** Christine Tedijanto, Yonatan H. Grad, Marc Lipsitch

**Appendix Table 1.** Notation, descriptions, and sources for variables in Equation 1.

**Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based on published etiology studies. Modifications were made if the reported proportion of bacterial cases for a given condition exceeded the estimated proportion of appropriate prescriptions reported in Fleming-Dutra et al.

**Appendix Figure 1.** Sensitivity analysis of proportions of avertable exposures across all outpatient conditions when proportion of unnecessary use is applied equally across target and bystander exposures.

**Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient conditions is eliminated against proportion of bystander exposures.

**Appendix Figure 3.** Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for acute sinusitis).

**Appendix Figure 4.** Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS data with and without NHAMCS outpatient department data.

476 **Appendix Table 1.** Notation, descriptions, and sources for variables in Equation 1.

Variable	Definition	Source
$d_{aig}$	Number of prescriptions (using nationally representative weights) of antibiotic $a$ associated with ICD9-CM diagnosis code $i$ in age group $g$	NAMCS/NHAMCS 2015
$e_{sig}$	Proportion of cases of condition defined by ICD9-CM diagnosis code $i$ in age group $g$ caused by species $s$	Published etiology studies
$p_{s0g}$	Asymptomatic carriage prevalence of species $s$ in age group $g$	Human Microbiome Project (HMP) and published carriage studies
$p_{sig}$	Carriage prevalence of species $s$ among individuals diagnosed with ICD9-CM code $i$ in age group $g$	$e_{sig} + (1 - e_{sig})p_{s0g}$
$q_{aig}$	Proportion of prescriptions of antibiotic $a$ associated with ICD9-CM diagnosis code $i$ in age group $g$ that are avertable under the given scenario	Fleming-Dutra et al. 2016 (Fleming-Dutra et al., 2016); note that this variable is only dependent on $a$ in the nitrofurantoin-specific scenario
$X_{as}$	Number of exposures of antibiotic $a$ experienced by species $s$ that are avertable under the given scenario	$\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig} \times q_{aig}$
$T_{as}$	Total number of exposures of antibiotic $a$ experienced by species $s$	$\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig}$

477  
478


479 **Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based  
 480 on published etiology studies and antibiotic use in NAMCS/NHAMCS. Modifications were  
 481 made if the reported proportion of bacterial cases for a given condition exceeded the estimated  
 482 proportion of appropriate prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al.,  
 483 2016)

Age group	Fleming-Dutra estimate	New estimate	Explanation
<b><i>Pharyngitis</i></b>			
0-19 years old	34%	Pharyngitis: 48%; Strep throat: 0%	Assuming that all strep-associated use of our antibiotics of interest (based on NAMCS/NHAMCS) was necessary, we estimated the proportion of non-strep pharyngitis antibiotic use that would have to be eliminated to maintain the overall estimate reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016)
20-64 years old	75%	Updated to 58% overall; Pharyngitis: 100%; Strep throat: 0%	
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.
<b><i>Sinusitis</i></b>			
0-19 years old	9%	Acute: 16%; Chronic: 0%	While acute sinusitis is rarely bacterial, bacteria are believed to play a much more prominent role in the etiology of chronic sinusitis (Brook, 2016). Thus, we assume that antibiotic use would only be eliminated from acute sinusitis and maintain the overall estimate of unnecessary use reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016) when possible.
20-64 years old	51%	Updated to 40% overall; Acute: 100%; Chronic: 0%	
>64 years old	16%	Acute: 34%; Chronic: 0%	
<b><i>Suppurative otitis media</i></b>			
0-19 years old	10%	10%	No change. Approximately 84% of pediatric cases were found to have bacterial growth (Bluestone, Stephenson, & Martin, 1992), so 10% is a reasonable estimate for avertable use.
20-64 years old	33%	26%	Based on an etiology study in adults, only 26% of cases were found to have no bacterial growth (Celin, 1991).
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.

484  
485




486 **Appendix Figure 1.** Sensitivity analysis of proportions of avertable exposures across all  
 487 outpatient conditions when proportion of unnecessary use is applied equally across target and  
 488 bystander exposures (Equation 1 without modification).  
 489



490  
 491  
 492 **Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,  
 493 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,  
 494 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,  
 495 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;  
 496 *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*,  
 497 SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years  
 498

499 **Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient  
500 conditions is eliminated against proportion of bystander exposures (Tedijanto et al., 2018).  
501



502  
503  
504

505 **Appendix Figure 3.** Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for  
 506 acute sinusitis).

507 **A. Use estimates of bacterial etiology to approximate appropriate antibiotic use for acute**  
 508 **sinusitis.** The following upper bound estimates for the proportion of acute sinusitis cases with  
 509 bacterial etiology were used: 2% for adults and 13% for children (applied to 0-19 year old age  
 510 group) (Sande & Gwaltney, 2004; Snow, Mottur-Pilson, Hickner, & for the American College of  
 511 Physicians–American Society of Internal Medicine\*, 2001; Wald, Guerra, & Byers, 1991).

	EC	HI	KP	MC	PA	SA	SAG	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	3	3	3	2	3	3	3	3	1	30.6
AMX-CLAV	13	13	12	4	14	12	10	12	6	62.4
PEN										0.0
<b>PENICILLINS</b>	<b>6</b>	<b>6</b>	<b>5</b>	<b>3</b>	<b>6</b>	<b>5</b>	<b>4</b>	<b>5</b>	<b>3</b>	<b>93.2</b>
AZM	5	5	4	2	5	4	4	4	4	44.9
CLI										0.0
CLR	8	8	7	3	9	8	7	8	8	4.4
<b>MACR/LINC</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>51.1</b>
CIP	1	1	1	1	1	1	1	1	1	6.8
LEV	4	4	4	4	3	4	4	4	4	12.2
MXF	1	1	1	0.2	1	1	0.4	1	1	0.4
<b>QUINOLONES</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>19.6</b>
CFL	1	1	1	7	1	1	2	2	1	4.2
CDR	4	4	3	4	2	3	4	4	1	4.9
<b>CEPHALOSPORINS</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>0.4</b>	<b>11.1</b>
DOX	4	4	4	4	4	4	4	4	3	9.8
TET										0.0
MNO										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>9.8</b>
TMP-SMX	1	1	1	0.3	1	1	1	1	1	3.7
NIT	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.4

512

513 **B. Use estimates of bacterial etiology among those presenting to primary care clinics.**  
 514 Patients visiting the clinic are likely to have more persistent, severe, or worsening symptoms,  
 515 which may be indications of bacterial etiology. Studies have estimated that approximately 38%  
 516 of adults and 17% of children (upper bounds) visiting primary care for symptoms of acute upper  
 517 respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger,  
 518 Holzer, & Lau, 2000; Williams, Simel, Roberts, & Samsa, 1992).

	EC	HI	KP	MC	PA	SA	SAG	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	3	3	2	2	3	3	2	3	1	30.6
AMX-CLAV	10	10	9	4	11	9	7	9	5	62.4
PEN										0.0
<b>PENICILLINS</b>	<b>5</b>	<b>5</b>	<b>4</b>	<b>2</b>	<b>5</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>2</b>	<b>93.2</b>
AZM	3	3	3	2	3	3	3	3	2	44.9
CLI										0.0
CLR	5	5	4	2	5	5	5	5	5	4.4
<b>MACR/LINC</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>51.1</b>
CIP	1	1	1	1	1	1	1	1	1	6.8
LEV	2	3	2	2	2	3	3	3	3	12.2
MXF	0.3	0.4	0.3	0.1	0.4	0.3	0.3	0.3	0.3	0.4
<b>QUINOLONES</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>19.6</b>
CFL	1	1	1	6	0.5	1	2	2	0.5	4.2
CDR	3	3	3	4	2	3	4	4	1	4.9
<b>CEPHALOSPORINS</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0.3</b>	<b>11.1</b>
DOX	2	2	2	2	2	2	2	2	2	9.8
TET										0.0
MNO										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>9.8</b>
TMP-SMX	1	1	0.4	0.2	0.4	0.5	0.4	0.5	0.5	3.7
NIT	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4

519




520

521 **Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,  
522 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,  
523 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,  
524 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):*  
525 EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*,  
526 SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years


527 **Appendix Figure 4.** Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS  
 528 data with (left) and without (right) NHAMCS outpatient department data.

529 **A. Eliminate unnecessary antibiotic use across all outpatient conditions.**




530

531 **B. Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics**  
 532 **are not indicated.**



533

534 **C. Eliminate all antibiotic use for acute sinusitis.**



535

536

537 **D. Prescribe nitrofurantoin for all cases of cystitis in women.**


AMX	1	1	1	0.4	1	0.5	0.5	0.5	0.2	5.8
AMX-CLAV	1	0.5	1	0.4	1	0.4	0.4	0.5	0.3	2.1
PEN	1	0.4	1	0.2	1	0.4	0.4	0.4	0.1	0.5
<b>PENICILLINS</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0.4</b>	<b>1</b>	<b>0.5</b>	<b>0.5</b>	<b>1</b>	<b>0.2</b>	<b>9.2</b>
AZM	0.4	0.3	0.4	0.1	1	0.2	0.2	0.2	0.2	2.6
CLI	3	2	4	1	6	2	2	2	2	4.4
CLR	1	0.4	1	0.2	1	0.4	0.3	0.4	0.4	0.3
<b>MACR/LINC</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0.2</b>	<b>1</b>	<b>1</b>	<b>0.4</b>	<b>0.5</b>	<b>0.5</b>	<b>7.9</b>
CIP	28	22	30	18	37	21	21	22	21	99.6
LEV	12	9	13	6	18	8	8	9	8	16.9
MXF	0.2	0.1	0.2	0.1	0.4	0.1	0.1	0.1	0.1	0.3
<b>QUINOLONES</b>	<b>17</b>	<b>13</b>	<b>18</b>	<b>7</b>	<b>25</b>	<b>12</b>	<b>11</b>	<b>12</b>	<b>12</b>	<b>117.2</b>
CFL	5	4	6	5	8	3	4	4	2	15.8
CDR	3	3	4	3	5	3	3	3	1	5.2
<b>CEPHALOSPORINS</b>	<b>5</b>	<b>4</b>	<b>6</b>	<b>4</b>	<b>9</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>44.0</b>
DOX	3	2	3	2	4	2	2	2	2	5.6
TET	2	2	3	1	4	2	2	2	2	0.4
MNO										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>4</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>6.0</b>
TMP-SMX	18	14	19	10	27	12	12	14	12	68.3
NIT										63.5

Weighted prescription rate (per 10,000 PY)

AMX	1	1	1	0.4	1	0.4	0.4	0.4	0.2	4.6
AMX-CLAV	1	1	1	0.5	1	0.5	0.5	1	0.3	2.0
PEN	1	0.4	1	0.2	1	0.4	0.3	0.4	0.1	0.4
<b>PENICILLINS</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0.4</b>	<b>1</b>	<b>0.5</b>	<b>0.5</b>	<b>0.5</b>	<b>0.2</b>	<b>7.9</b>
AZM	0.4	0.3	0.4	0.1	1	0.2	0.2	0.2	0.2	2.4
CLI	4	3	4	1	6	2	2	2	2	4.4
CLR										0.0
<b>MACR/LINC</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0.2</b>	<b>1</b>	<b>1</b>	<b>0.4</b>	<b>0.5</b>	<b>0.5</b>	<b>7.3</b>
CIP	27	22	29	17	37	21	20	21	20	90.0
LEV	12	9	14	7	19	9	8	9	8	16.8
MXF	0.1	0.1	0.1	0	0.3	0.1	0.1	0.1	0.1	0.2
<b>QUINOLONES</b>	<b>17</b>	<b>13</b>	<b>18</b>	<b>7</b>	<b>25</b>	<b>12</b>	<b>11</b>	<b>12</b>	<b>12</b>	<b>107.4</b>
CFL	5	4	6	5	8	3	4	4	2	14.4
CDR	3	3	4	3	6	3	3	3	1	5.2
<b>CEPHALOSPORINS</b>	<b>6</b>	<b>4</b>	<b>6</b>	<b>5</b>	<b>9</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>41.4</b>
DOX	3	2	3	2	5	2	2	2	2	5.3
TET	2	1	2	1	3	1	1	1	1	0.2
MNO										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>1</b>	<b>4</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>5.6</b>
TMP-SMX	19	15	20	10	28	13	13	14	12	63.4
NIT										58.1

Weighted prescription rate (per 10,000 PY)

538



539  
540  
541  
542  
543  
544  
545

**Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin, AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides, CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline, TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years